IL154784A0 - Pyrazole derivatives and pharmaceutical compositions containing the same - Google Patents
Pyrazole derivatives and pharmaceutical compositions containing the sameInfo
- Publication number
- IL154784A0 IL154784A0 IL15478401A IL15478401A IL154784A0 IL 154784 A0 IL154784 A0 IL 154784A0 IL 15478401 A IL15478401 A IL 15478401A IL 15478401 A IL15478401 A IL 15478401A IL 154784 A0 IL154784 A0 IL 154784A0
- Authority
- IL
- Israel
- Prior art keywords
- same
- pharmaceutical compositions
- compositions containing
- pyrazole derivatives
- pyrazole
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23279500P | 2000-09-15 | 2000-09-15 | |
US25788700P | 2000-12-21 | 2000-12-21 | |
US28694901P | 2001-04-27 | 2001-04-27 | |
PCT/US2001/028940 WO2002022607A1 (en) | 2000-09-15 | 2001-09-14 | Pyrazole compounds useful as protein kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
IL154784A0 true IL154784A0 (en) | 2003-10-31 |
Family
ID=27398347
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL15478601A IL154786A0 (en) | 2000-09-15 | 2001-09-14 | Pyrazole derivatives and pharmaceutical compositions containing the same |
IL15478401A IL154784A0 (en) | 2000-09-15 | 2001-09-14 | Pyrazole derivatives and pharmaceutical compositions containing the same |
IL15474701A IL154747A0 (en) | 2000-09-15 | 2001-09-14 | Pyrazole derivatives and pharmaceutical compositions containing the same |
IL15481701A IL154817A0 (en) | 2000-09-15 | 2001-09-14 | Pyrazole derivatives and pharmaceutical compositions containing the same |
IL154747A IL154747A (en) | 2000-09-15 | 2003-03-04 | History of pyrazole and pharmaceutical preparations containing them |
IL154784A IL154784A (en) | 2000-09-15 | 2003-03-06 | History of pyrazole and pharmaceutical preparations containing them |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL15478601A IL154786A0 (en) | 2000-09-15 | 2001-09-14 | Pyrazole derivatives and pharmaceutical compositions containing the same |
Family Applications After (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL15474701A IL154747A0 (en) | 2000-09-15 | 2001-09-14 | Pyrazole derivatives and pharmaceutical compositions containing the same |
IL15481701A IL154817A0 (en) | 2000-09-15 | 2001-09-14 | Pyrazole derivatives and pharmaceutical compositions containing the same |
IL154747A IL154747A (en) | 2000-09-15 | 2003-03-04 | History of pyrazole and pharmaceutical preparations containing them |
IL154784A IL154784A (en) | 2000-09-15 | 2003-03-06 | History of pyrazole and pharmaceutical preparations containing them |
Country Status (24)
Country | Link |
---|---|
US (7) | US6638926B2 (no) |
EP (8) | EP1317447B1 (no) |
JP (9) | JP4170752B2 (no) |
KR (4) | KR20030030005A (no) |
CN (3) | CN100355750C (no) |
AP (1) | AP2003002762A0 (no) |
AT (8) | ATE294797T1 (no) |
AU (9) | AU2001296871A1 (no) |
BR (1) | BR0114088A (no) |
CA (8) | CA2422299C (no) |
DE (8) | DE60119749T2 (no) |
DK (1) | DK1318997T3 (no) |
ES (3) | ES2266258T3 (no) |
HK (8) | HK1057543A1 (no) |
HU (4) | HUP0401819A3 (no) |
IL (6) | IL154786A0 (no) |
MX (8) | MXPA03002294A (no) |
NO (4) | NO327708B1 (no) |
NZ (4) | NZ525008A (no) |
PE (1) | PE20020451A1 (no) |
PL (1) | PL361676A1 (no) |
PT (2) | PT1317448E (no) |
TW (1) | TWI303636B (no) |
WO (8) | WO2002022603A1 (no) |
Families Citing this family (400)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1953417B (zh) * | 1996-09-04 | 2010-12-29 | 英特托拉斯技术公司 | 一种从用户站点向外部站点发布使用数据的方法 |
US6184226B1 (en) * | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
US6982260B1 (en) | 1999-11-22 | 2006-01-03 | Warner-Lambert Company | Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes |
SK288019B6 (sk) | 1999-12-24 | 2012-11-05 | Aventis Pharma Limited | Azaindoles derivatives, their use and pharmaceutical composition containing thereof |
US6660731B2 (en) * | 2000-09-15 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US6638926B2 (en) * | 2000-09-15 | 2003-10-28 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US7473691B2 (en) * | 2000-09-15 | 2009-01-06 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
EP1347972A1 (en) * | 2000-12-19 | 2003-10-01 | Smithkline Beecham Plc | Pyrazolo 3,4-c]pyridines as gsk-3 inhibitors |
CN100436452C (zh) * | 2000-12-21 | 2008-11-26 | 沃泰克斯药物股份有限公司 | 可用作蛋白激酶抑制剂的吡唑化合物 |
MXPA03005696A (es) * | 2000-12-21 | 2003-10-06 | Glaxo Group Ltd | Pirimidinaminas como moduladores de angiogenesis. |
WO2002079163A1 (en) * | 2001-03-30 | 2002-10-10 | Smithkline Beecham Corporation | Aminopyridine derivatives as estrogen receptor modulators |
JP4316893B2 (ja) | 2001-05-16 | 2009-08-19 | バーテックス ファーマシューティカルズ インコーポレイテッド | Srcおよび他のプロテインキナーゼのインヒビター |
GB0115109D0 (en) | 2001-06-21 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
US6939874B2 (en) | 2001-08-22 | 2005-09-06 | Amgen Inc. | Substituted pyrimidinyl derivatives and methods of use |
US7115617B2 (en) | 2001-08-22 | 2006-10-03 | Amgen Inc. | Amino-substituted pyrimidinyl derivatives and methods of use |
US20030176437A1 (en) | 2001-08-31 | 2003-09-18 | D.M. Watterson | Anti-inflammatory and protein kinase inhibitor compositions and related methods for downregulation of detrimental cellular responses and inhibition of cell death |
WO2003030909A1 (en) * | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer |
JP4542338B2 (ja) | 2001-09-26 | 2010-09-15 | ファイザー イタリア ソシエタ ア レスポンサビリタ リミタータ | キナーゼ阻害因子として活性なアミノインダゾール誘導体、それらの製造方法及びそれらを含有する医薬組成物 |
TWI330183B (no) * | 2001-10-22 | 2010-09-11 | Eisai R&D Man Co Ltd | |
SE0104140D0 (sv) * | 2001-12-07 | 2001-12-07 | Astrazeneca Ab | Novel Compounds |
EP2198867A1 (en) | 2001-12-07 | 2010-06-23 | Vertex Pharmaceuticals, Inc. | Pyrimidine-based compounds useful as GSK-3 inhibitors |
US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
AU2002357164A1 (en) | 2001-12-17 | 2003-06-30 | Smithkline Beecham Corporation | Pyrazolopyridazine derivatives |
US20030158195A1 (en) | 2001-12-21 | 2003-08-21 | Cywin Charles L. | 1,6 naphthyridines useful as inhibitors of SYK kinase |
WO2003055866A1 (en) * | 2001-12-21 | 2003-07-10 | Bayer Pharmaceuticals Corporation | Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents |
EP1471910A2 (en) * | 2002-01-17 | 2004-11-03 | Neurogen Corporation | Substituted quinazolin-4-ylamine analogues as modulators of capsaicin receptors |
TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
US20040034037A1 (en) * | 2002-02-06 | 2004-02-19 | Harbeson Scott L. | Heteroaryl compounds useful as inhibitors of GSK-3 |
ATE466580T1 (de) | 2002-03-15 | 2010-05-15 | Vertex Pharma | Azolylaminoazine als proteinkinasehemmer |
AU2003225800A1 (en) | 2002-03-15 | 2003-09-29 | Hayley Binch | Azolylaminoazine as inhibitors of protein kinases |
EP1485380B1 (en) * | 2002-03-15 | 2010-05-19 | Vertex Pharmaceuticals Incorporated | Azolylaminoazines as inhibitors of protein kinases |
CA2479520A1 (en) * | 2002-04-05 | 2003-10-16 | Birgit Jung | P38 kinase inhibitors for treating mucus hypersecretion_ |
ES2340475T3 (es) | 2002-05-01 | 2010-06-04 | Vertex Pharmaceuticals Incorporated | Estructura cristalizada de proteina aurora-2 y sus bolsillos de union. |
ATE493987T1 (de) * | 2002-05-22 | 2011-01-15 | Amgen Inc | Aminopyrimidin-derivate zur verwendung als vanilloid-rezeptor-liganden zur behandlung von schmerzen |
AU2003242252A1 (en) | 2002-06-07 | 2003-12-22 | Kyowa Hakko Kogyo Co., Ltd. | Bicyclic pyrimidine derivatives |
AU2003251721A1 (en) | 2002-06-14 | 2003-12-31 | Laboratoires Serono Sa | Azole methylidene cyanide derivatives and their use as protein kinase modulators |
MY141867A (en) * | 2002-06-20 | 2010-07-16 | Vertex Pharma | Substituted pyrimidines useful as protein kinase inhibitors |
AU2003249369A1 (en) | 2002-06-21 | 2004-01-06 | Cellular Genomics, Inc. | Certain amino-substituted monocycles as kinase modulators |
DE60320560T2 (de) * | 2002-07-17 | 2008-12-11 | Pfizer Italia S.R.L. | Heterobicyclische pyrazolderivate als kinaseinhibitoren |
CA2494367A1 (en) * | 2002-07-25 | 2004-02-05 | Scios Inc. | Methods for improvement of lung function using tgf-.beta. inhibitors |
CN1678321A (zh) | 2002-07-29 | 2005-10-05 | 里格尔药品股份有限公司 | 用2,4-嘧啶二胺化合物治疗或者预防自体免疫性疾病的方法 |
SI1532145T1 (sl) * | 2002-08-02 | 2007-02-28 | Vertex Pharma | Pirazolni sestavki, koristni kot inhibitorji GSK-3 |
CN101037438A (zh) * | 2002-08-02 | 2007-09-19 | 沃泰克斯药物股份有限公司 | 用作gsk-3的抑制剂的吡唑组合物 |
DE60325865D1 (de) * | 2002-08-13 | 2009-03-05 | Merck Sharp & Dohme | Phenylpyridazin derivative als liganden für gaba-rezeptoren |
BR0313397A (pt) | 2002-08-14 | 2005-06-28 | Vertex Pharmaceuticals Incorpo | Inibidores de proteina cinase e usos destes |
KR101166745B1 (ko) | 2002-09-05 | 2012-07-23 | 아방티 파르마 소시에테 아노님 | 의약으로서의 신규한 아미노인다졸 유도체 및 이를 함유하는 약제학적 조성물 |
FR2844267B1 (fr) * | 2002-09-05 | 2008-02-15 | Aventis Pharma Sa | Nouveaux derives d'aminoindazoles a titre de medicaments et compositions pharmaceutiques les renfermant |
UA80295C2 (en) | 2002-09-06 | 2007-09-10 | Biogen Inc | Pyrazolopyridines and using the same |
CN1694708A (zh) * | 2002-09-10 | 2005-11-09 | 西奥斯股份有限公司 | TGFβ的抑制剂 |
CA2506772A1 (en) | 2002-11-01 | 2004-05-21 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of jak and other protein kinases |
CA2507406A1 (en) | 2002-11-05 | 2004-05-21 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of jak and other protein kinases |
WO2004048365A1 (en) * | 2002-11-21 | 2004-06-10 | Chiron Corporation | 2,4,6-trisubstituted pyrimidines as phosphotidylinositol (pi) 3-kinase inhibitors and their use in the treatment of cancer |
SI2316831T1 (sl) * | 2002-11-21 | 2013-07-31 | Novartis Ag | 2-(morfolin-4-il)pirimidini kot inhibitorji fosfotidilinozitol (PI) 3-kinaze in njihova uporaba pri zdravljenju raka |
US7759336B2 (en) * | 2002-12-10 | 2010-07-20 | Ono Pharmaceutical Co., Ltd. | Nitrogen-containing heterocyclic compounds and medicinal use thereof |
FR2848554A1 (fr) * | 2002-12-12 | 2004-06-18 | Aventis Pharma Sa | Nouveaux derives d'aminoindazoles a titre de medicaments et compositions pharmaceutiques les renfermant |
PL376789A1 (pl) | 2002-12-12 | 2006-01-09 | Aventis Pharma S.A. | Pochodne aminoindazoli i ich zastosowanie jako inhibitorów kinazy |
BR0317168A (pt) | 2002-12-13 | 2005-11-01 | Neurogen Corp | Composto ou uma forma farmaceuticamente aceitável do mesmo, composição farmacêutica, métodos de reduzir condutância de cálcio de um receptor de capsaicina celular, e de inibir ligação de ligante vanilóide a um receptor de capsaicina, métodos de tratar uma condição responsiva à modulação de receptor de capsaicina, dor, coceira, tosse ou soluços, incontinência urinária, de promover perda de peso em paciente, e de determinar a presença ou ausência de receptor de capsaicina em uma amostra, preparação farmacêutica embalada, e, uso de um composto |
WO2004072029A2 (en) * | 2003-02-06 | 2004-08-26 | Vertex Pharmaceuticals Incorporated | Pyrazolopyridazines useful as inhibitors of protein kinases |
US7157455B2 (en) * | 2003-02-10 | 2007-01-02 | Hoffmann-La Roche Inc. | 4-Aminopyrimidine-5-one derivatives |
JP2006521398A (ja) * | 2003-03-28 | 2006-09-21 | サイオス・インコーポレーテツド | TGFβの二−環式ピリミジン阻害剤 |
AU2004230928B2 (en) * | 2003-04-09 | 2010-12-02 | Exelixis, Inc. | Tie-2 modulators and methods of use |
WO2004096130A2 (en) * | 2003-04-24 | 2004-11-11 | Merck & Co., Inc. | Inhibitors of akt activity |
WO2004096808A1 (en) * | 2003-04-28 | 2004-11-11 | De Novo Pharmaceuticals Limited | Triazine compounds and their use |
CA2528834A1 (en) * | 2003-06-13 | 2005-02-10 | Arena Pharmaceuticals, Inc. | 5-substituted 2h-pyrazole-3-carboxylic acid derivatives as agonists for the nicotinic acid receptor rup25 for the treatment of dyslipidemia and related diseases |
MXPA05013922A (es) * | 2003-06-20 | 2006-02-24 | Coley Pharm Group Inc | Antagonistas de receptor tipo toll de molecula pequena. |
TW200510373A (en) | 2003-07-14 | 2005-03-16 | Neurogen Corp | Substituted quinolin-4-ylamine analogues |
US7329664B2 (en) | 2003-07-16 | 2008-02-12 | Neurogen Corporation | Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues |
PL2256106T3 (pl) | 2003-07-22 | 2015-08-31 | Astex Therapeutics Ltd | Związki 3,4-pochodne 1h-pirazolu i ich zastosowanie jako kinazy zależne od cyklin (cdk) i modulatory kinazy syntazy glikogenu-3 (gsk-3) |
US7122542B2 (en) | 2003-07-30 | 2006-10-17 | Rigel Pharmaceuticals, Inc. | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds |
EP1663994B1 (en) * | 2003-08-05 | 2012-03-07 | Vertex Pharmaceuticals Incorporated | Tetrahydroquinazoline compounds as inhibitors of voltage-gated ion channels |
JP4889489B2 (ja) * | 2003-08-06 | 2012-03-07 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼのインヒビターとして有用なアミノトリアゾール化合物 |
EP1668013B1 (en) * | 2003-09-23 | 2012-02-22 | Vertex Pharmaceuticals Incorporated | Pyrazolopyrrole derivatives as protein kinase inhibitors |
GB0323137D0 (en) | 2003-10-03 | 2003-11-05 | Chang Lisa C W | 2,4,6- Trisubstituted pyrimidines and their different uses |
KR20060123164A (ko) | 2003-10-17 | 2006-12-01 | 아스트라제네카 아베 | 암 치료에 사용하기 위한 4-(피라졸-3-일아미노)피리미딘유도체 |
WO2005047268A2 (en) * | 2003-11-10 | 2005-05-26 | X-Ceptor Therapeutics, Inc. | Substituted pyrimidine compositions and methods of use |
US7338951B2 (en) | 2003-11-10 | 2008-03-04 | Synta Pharmaceuticals Corp. | Pyridine compounds |
CN102127056B (zh) * | 2003-12-03 | 2013-08-21 | Ym生物科学澳大利亚私人有限公司 | 微管蛋白抑制剂 |
CN1902193B (zh) * | 2003-12-04 | 2011-07-13 | 沃泰克斯药物股份有限公司 | 可用作蛋白激酶抑制剂的喹喔啉 |
EP1709045A1 (en) * | 2003-12-09 | 2006-10-11 | Vertex Pharmaceuticals Incorporated | Naphthyridine derivatives and their use as modulators of muscarinic receptors |
EP1694686A1 (en) * | 2003-12-19 | 2006-08-30 | Takeda San Diego, Inc. | Kinase inhibitors |
TW200530235A (en) | 2003-12-24 | 2005-09-16 | Renovis Inc | Bicycloheteroarylamine compounds as ion channel ligands and uses thereof |
KR20070026390A (ko) | 2004-01-23 | 2007-03-08 | 암젠 인코포레이션 | 화합물 및 사용방법 |
WO2005073224A2 (en) | 2004-01-23 | 2005-08-11 | Amgen Inc | Quinoline quinazoline pyridine and pyrimidine counds and their use in the treatment of inflammation angiogenesis and cancer |
CA2556239A1 (en) | 2004-02-11 | 2005-08-25 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
EP1742936A2 (en) | 2004-04-13 | 2007-01-17 | Icagen, Inc. | Polycyclic pyridines as potassium ion channel modulators |
EP1763524A1 (en) * | 2004-04-23 | 2007-03-21 | Takeda San Diego, Inc. | Indole derivatives and use thereof as kinase inhibitors |
US7793137B2 (en) | 2004-10-07 | 2010-09-07 | Cisco Technology, Inc. | Redundant power and data in a wired data telecommunincations network |
PT1905773E (pt) | 2004-05-14 | 2012-10-25 | Millennium Pharm Inc | Compostos e métodos para inibir a progressão mitótica por inibição da quinase aurora |
EP1604988A1 (en) * | 2004-05-18 | 2005-12-14 | Sanofi-Aventis Deutschland GmbH | Pyridazinone derivatives, methods for producing them and their use as pharmaceuticals |
EP1598348A1 (en) * | 2004-05-18 | 2005-11-23 | Aventis Pharma Deutschland GmbH | Novel pyridazinone derivatives as inhibitors of CDK2 |
DE102004028862A1 (de) * | 2004-06-15 | 2005-12-29 | Merck Patent Gmbh | 3-Aminoindazole |
GB0415364D0 (en) * | 2004-07-09 | 2004-08-11 | Astrazeneca Ab | Pyrimidine derivatives |
US20080261821A1 (en) * | 2004-07-21 | 2008-10-23 | The Regents Of Te University Of California | Mechanism-Based Crosslinkers |
JP2008510734A (ja) * | 2004-08-18 | 2008-04-10 | タケダ サン ディエゴ インコーポレイテッド | キナーゼ阻害剤 |
WO2006018256A2 (en) | 2004-08-19 | 2006-02-23 | Dsm Ip Assets B.V. | Process for the rectification of mixtures of high-boiling air-and/or temperature-sensitive useful products |
GB0419416D0 (en) | 2004-09-01 | 2004-10-06 | Inst Of Ex Botany Ascr | 4-Arylazo-3,5-Diamino-Pyrazole compounds and use thereof |
US7335672B2 (en) | 2004-09-13 | 2008-02-26 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
CA2581454A1 (en) * | 2004-09-23 | 2006-03-30 | Reddy Us Therapeutics, Inc. | Novel pyrimidine compounds, process for their preparation and compositions containing them |
AR050948A1 (es) | 2004-09-24 | 2006-12-06 | Hoffmann La Roche | Derivados de ftalazinona; su obtencion y su utilizacion en la fabricacion de medicamentos para el tratamiento del cancer. |
US7285569B2 (en) | 2004-09-24 | 2007-10-23 | Hoff Hoffmann-La Roche Inc. | Tricycles, their manufacture and use as pharmaceutical agents |
TW200626157A (en) | 2004-09-30 | 2006-08-01 | Tibotec Pharm Ltd | HCV inhibiting bi-cyclic pyrimidines |
TW200621251A (en) | 2004-10-12 | 2006-07-01 | Neurogen Corp | Substituted biaryl quinolin-4-ylamine analogues |
US7713973B2 (en) | 2004-10-15 | 2010-05-11 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
TW200621257A (en) * | 2004-10-20 | 2006-07-01 | Astellas Pharma Inc | Pyrimidine derivative fused with nonaromatic ring |
WO2006050389A2 (en) | 2004-11-02 | 2006-05-11 | Northwestern University | Pyridazine compounds, compositions and methods |
CA2589102C (en) | 2004-11-02 | 2013-08-13 | Northwestern University | Pyridazine compounds and methods for using the compounds to treat inflammatory diseases |
JP2008520713A (ja) | 2004-11-17 | 2008-06-19 | ミイカナ セラピューティクス インコーポレイテッド | キナーゼ阻害剤 |
DK1814878T3 (da) | 2004-11-24 | 2012-05-07 | Rigel Pharmaceuticals Inc | Spiro-2, 4-pyrimidindiamin-forbindelser og anvendelser deraf |
US7652009B2 (en) | 2004-11-30 | 2010-01-26 | Amgem Inc. | Substituted heterocycles and methods of use |
US20060128710A1 (en) * | 2004-12-09 | 2006-06-15 | Chih-Hung Lee | Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof |
CA2588220A1 (en) * | 2004-12-23 | 2006-06-29 | Pfizer Products Inc. | Heteroaromatic derivatives useful as anticancer agents |
JP5208516B2 (ja) * | 2004-12-30 | 2013-06-12 | エグゼリクシス, インコーポレイテッド | キナーゼモジュレーターとしてのピリミジン誘導体および使用方法 |
DK1856135T3 (da) | 2005-01-19 | 2010-04-12 | Rigel Pharmaceuticals Inc | Prodrugs af 2,4-pyrimidindiamin-forbindelser og deres anvendelser |
US8404718B2 (en) | 2005-01-21 | 2013-03-26 | Astex Therapeutics Limited | Combinations of pyrazole kinase inhibitors |
AR054425A1 (es) | 2005-01-21 | 2007-06-27 | Astex Therapeutics Ltd | Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico. |
JP4804480B2 (ja) * | 2005-01-26 | 2011-11-02 | シェーリング コーポレイション | 癌の処置のためのプロテインキナーゼインヒビターとしての、3−(インダゾール−5−イル)−(1,2,4)トリアジン誘導体、および関連する化合物 |
SI2383268T1 (sl) | 2005-02-04 | 2016-02-29 | Astrazeneca Ab | Derivati pirazolilaminopiridina uporabni kot kinazni inhibitorji |
US20060178388A1 (en) | 2005-02-04 | 2006-08-10 | Wrobleski Stephen T | Phenyl-substituted pyrimidine compounds useful as kinase inhibitors |
PT1853588E (pt) | 2005-02-16 | 2008-08-25 | Astrazeneca Ab | Compostos químicos |
US20080161278A1 (en) * | 2005-03-23 | 2008-07-03 | Astrazeneca Ab | 2-Azetidinyl-4-(1H-Pyrazol-3-Ylamino) Pyrimidines as Inhibitors of Insulin-Like Growth Factor-1 Receptor Activity |
US7402596B2 (en) | 2005-03-24 | 2008-07-22 | Renovis, Inc. | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof |
ATE517897T1 (de) | 2005-03-25 | 2011-08-15 | Tibotec Pharm Ltd | Heterobicyclische inhibitoren von hvc |
DK1869032T3 (da) * | 2005-04-05 | 2008-11-10 | Astrazeneca Ab | Pyrimidindervater til anvendelse som anticancermidler |
GB0507347D0 (en) * | 2005-04-12 | 2005-05-18 | Astrazeneca Ab | Chemical compounds |
US7462639B2 (en) | 2005-04-14 | 2008-12-09 | Hoffmann-La Roche Inc. | Aminopyrazole derivatives |
JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
WO2006118231A1 (ja) | 2005-04-28 | 2006-11-09 | Mitsubishi Tanabe Pharma Corporation | シアノピリジン誘導体及びその医薬としての用途 |
EP1885454A2 (en) | 2005-05-04 | 2008-02-13 | DeveloGen Aktiengesellschaft | Use of gsk-3 inhibitors for preventing and treating pancreatic autoimmune disorders |
ES2552804T3 (es) * | 2005-05-04 | 2015-12-02 | Evotec Ag | Compuestos heterocíclicos condensados, y sus composiciones y usos |
US20080194606A1 (en) * | 2005-05-05 | 2008-08-14 | Astrazeneca | Pyrazolyl-Amino-Substituted Pyrimidines and Their Use in the Treatment of Cancer |
AR056347A1 (es) | 2005-05-12 | 2007-10-03 | Tibotec Pharm Ltd | Uso de compuestos de pteridina para fabricar medicamentos y composiciones farmaceuticas |
CA2608009A1 (en) | 2005-05-16 | 2006-11-23 | Astrazeneca Ab | Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors |
CA2612788A1 (en) | 2005-06-24 | 2006-12-28 | Steven Cesar Alfons De Jonghe | Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for treating hepatitis c |
ES2270715B1 (es) | 2005-07-29 | 2008-04-01 | Laboratorios Almirall S.A. | Nuevos derivados de pirazina. |
CA2619517A1 (en) * | 2005-08-18 | 2007-02-22 | Michael Mortimore | Pyrazine kinase inhibitors |
WO2007023382A2 (en) * | 2005-08-25 | 2007-03-01 | Pfizer Inc. | Pyrimidine amino pyrazole compounds, potent kinase inhibitors |
EP2258359A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
EP2275095A3 (en) | 2005-08-26 | 2011-08-17 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
EP1934219A1 (en) | 2005-09-16 | 2008-06-25 | Ranbaxy Laboratories Limited | Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors |
KR20140025610A (ko) * | 2005-09-30 | 2014-03-04 | 미카나 테라퓨틱스, 인크. | 치환된 피라졸 화합물 |
CN101316587B (zh) * | 2005-09-30 | 2013-04-03 | 迈卡纳治疗股份有限公司 | 取代的吡唑化合物 |
ES2274712B1 (es) | 2005-10-06 | 2008-03-01 | Laboratorios Almirall S.A. | Nuevos derivados imidazopiridina. |
US8119655B2 (en) * | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
GB0520657D0 (en) * | 2005-10-11 | 2005-11-16 | Ludwig Inst Cancer Res | Pharmaceutical compounds |
EP2377530A3 (en) | 2005-10-21 | 2012-06-20 | Braincells, Inc. | Modulation of neurogenesis by PDE inhibition |
ES2391783T3 (es) | 2005-10-28 | 2012-11-29 | Astrazeneca Ab | Derivados de 4-(3-aminopirazol)pirimidina para su uso como agentes inhibidores de las tirosina cinasas en el tratamiento del cáncer |
EP2314289A1 (en) | 2005-10-31 | 2011-04-27 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
AU2006311830B2 (en) * | 2005-11-03 | 2013-03-14 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
EP2404919B1 (en) | 2005-11-08 | 2013-08-21 | Vertex Pharmaceuticals Incorporated | Heterocyclic compound useful as a modulator of ATP-binding cassette transporters. |
US7713987B2 (en) | 2005-12-06 | 2010-05-11 | Rigel Pharmaceuticals, Inc. | Pyrimidine-2,4-diamines and their uses |
US8546404B2 (en) | 2005-12-13 | 2013-10-01 | Merck Sharp & Dohme | Compounds that are ERK inhibitors |
US7572809B2 (en) | 2005-12-19 | 2009-08-11 | Hoffmann-La Roche Inc. | Isoquinoline aminopyrazole derivatives |
CA2633584A1 (en) * | 2005-12-20 | 2007-07-05 | Takeda Pharmaceutical Company Limited | Glucokinase activators |
WO2007084557A2 (en) | 2006-01-17 | 2007-07-26 | Vertex Pharmaceuticals Incorporated | Azaindoles useful as inhibitors of janus kinases |
JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
EP1984331B1 (en) | 2006-02-16 | 2010-10-20 | Schering Corporation | Pyrrolidine derivatives as erk inhibitors |
US20100216734A1 (en) * | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
AU2007223036A1 (en) * | 2006-03-08 | 2007-09-13 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
PE20080145A1 (es) * | 2006-03-21 | 2008-02-11 | Janssen Pharmaceutica Nv | Tetrahidro-pirimidoazepinas como moduladores de trpv1 |
AU2007235237B2 (en) * | 2006-04-11 | 2011-08-18 | Vertex Pharmaceuticals Incorporated | Thiazoles, imidazoles, and pyrazoles useful as inhibitors of protein kinases |
CA2650711A1 (en) | 2006-04-28 | 2007-11-08 | Northwestern University | Compositions and treatments using pyridazine compounds and cholinesterase inhibitors |
WO2007134077A2 (en) * | 2006-05-09 | 2007-11-22 | Braincells, Inc. | 5 ht receptor mediated neurogenesis |
CA2651813A1 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
US20100009983A1 (en) * | 2006-05-09 | 2010-01-14 | Braincells, Inc. | 5 ht receptor mediated neurogenesis |
PT2248812E (pt) | 2006-06-27 | 2014-03-12 | Takeda Pharmaceutical | Compostos cíclicos fundidos como moduladores do receptor gpr40 |
JP2009541480A (ja) * | 2006-06-30 | 2009-11-26 | アストラゼネカ アクチボラグ | 癌の治療において有用なピリミジン誘導体 |
WO2008005538A2 (en) * | 2006-07-05 | 2008-01-10 | Exelixis, Inc. | Methods of using igf1r and abl kinase modulators |
EP2049500B1 (en) | 2006-07-06 | 2011-09-07 | Array Biopharma, Inc. | Cyclopenta [d] pyrimidines as akt protein kinase inhibitors |
US8063050B2 (en) | 2006-07-06 | 2011-11-22 | Array Biopharma Inc. | Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
UA95641C2 (en) * | 2006-07-06 | 2011-08-25 | Эррей Биофарма Инк. | Hydroxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors |
US8338435B2 (en) | 2006-07-20 | 2012-12-25 | Gilead Sciences, Inc. | Substituted pyrido(3,2-D) pyrimidines and pharmaceutical compositions for treating viral infections |
AU2007292848A1 (en) * | 2006-09-08 | 2008-03-13 | Braincells, Inc. | Combinations containing a 4-acylaminopyridine derivative |
AU2007299920A1 (en) * | 2006-09-19 | 2008-03-27 | Braincells, Inc. | PPAR Mediated Modulation of Neurogenesis |
US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
EP2223925A1 (en) * | 2006-10-09 | 2010-09-01 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
US20100120717A1 (en) | 2006-10-09 | 2010-05-13 | Brown Jason W | Kinase inhibitors |
US8642598B2 (en) | 2006-10-21 | 2014-02-04 | Abbvie Inc. | Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors |
AU2007317435A1 (en) * | 2006-11-02 | 2008-05-15 | Vertex Pharmaceuticals Incorporated | Aminopyridines and aminopyrimidines useful as inhibitors of protein kinases |
WO2008077086A1 (en) * | 2006-12-19 | 2008-06-26 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as inhibitors of protein kinases |
WO2008077650A1 (en) | 2006-12-26 | 2008-07-03 | Gilead Sciences, Inc. | Pyrido(3,2-d)pyrimidines useful for treating viral infections |
US8143394B2 (en) | 2006-12-26 | 2012-03-27 | Gilead Sciences, Inc. | Pyrido(3,2-d)pyrimidines useful for treating viral infections |
TW200840584A (en) | 2006-12-26 | 2008-10-16 | Gilead Sciences Inc | Pyrido(3,2-d)pyrimidines useful for treating viral infections |
AU2008213808B2 (en) | 2007-02-06 | 2011-11-10 | Novartis Ag | PI 3-kinase inhibitors and methods of their use |
EP2121633A2 (en) * | 2007-02-12 | 2009-11-25 | Merck & Co., Inc. | Piperazine derivatives for treatment of ad and related conditions |
EP2120573A4 (en) * | 2007-02-12 | 2011-05-25 | Merck Sharp & Dohme | DERIVATIVES OF PIPERIDINE |
JPWO2008111441A1 (ja) | 2007-03-05 | 2010-06-24 | 協和発酵キリン株式会社 | 医薬組成物 |
JP5520057B2 (ja) * | 2007-03-09 | 2014-06-11 | バーテックス ファーマシューティカルズ インコーポレイテッド | 蛋白キナーゼの阻害剤として有用なアミノピリミジン |
JP5393489B2 (ja) * | 2007-03-09 | 2014-01-22 | バーテックス ファーマシューティカルズ インコーポレイテッド | 蛋白キナーゼの阻害剤として有用なアミノピリミジン |
NZ579483A (en) * | 2007-03-09 | 2012-07-27 | Vertex Pharma | Aminopyridines useful as inhibitors of protein kinases |
MX2009011059A (es) | 2007-04-13 | 2009-11-26 | Vertex Pharma | Aminopirimidinas utiles como inhibidores de cinasas. |
JP2010524911A (ja) * | 2007-04-18 | 2010-07-22 | アストラゼネカ アクチボラグ | 5−アミノピラゾール−3−イル−3H−イミダゾ[4,5−b]ピリジン誘導体と癌の治療のためのその使用 |
WO2008137621A1 (en) * | 2007-05-02 | 2008-11-13 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
MX2009011811A (es) * | 2007-05-02 | 2010-01-14 | Vertex Pharma | Aminopirimidinas utiles como inhibidores de cinasa. |
CA2685876A1 (en) | 2007-05-02 | 2008-11-13 | Vertex Pharmaceuticals Incorporated | Thiazoles and pyrazoles useful as kinase inhibitors |
JP2010526048A (ja) * | 2007-05-04 | 2010-07-29 | アストラゼネカ アクチボラグ | アミノ−チアゾリル−ピリミジン誘導体、および癌の治療のための該誘導体の使用 |
UA99459C2 (en) * | 2007-05-04 | 2012-08-27 | Астразенека Аб | 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer |
US8969386B2 (en) | 2007-05-09 | 2015-03-03 | Vertex Pharmaceuticals Incorporated | Modulators of CFTR |
EP2164842A2 (en) * | 2007-05-24 | 2010-03-24 | Vertex Pharmaceuticals Incorporated | Thiazoles and pyrazoles useful as kinase inhibitors |
JP2010529193A (ja) * | 2007-06-11 | 2010-08-26 | ミイカナ セラピューティクス インコーポレイテッド | 置換ピラゾール化合物 |
US8242150B2 (en) * | 2007-06-13 | 2012-08-14 | Merck Sharp & Dohme Corp. | Triazole derivatives for treating alzheimer'S disease and related conditions |
US7956190B2 (en) | 2007-06-25 | 2011-06-07 | Hoffmann-La Roche Inc. | Benzimidazole amido derivatives as kinase inhibitors |
RU2486181C2 (ru) | 2007-07-05 | 2013-06-27 | Эррэй Биофарма Инк. | Пиримидилциклопентаны как ингибиторы акт-протеинкиназ |
SI2173723T1 (sl) * | 2007-07-05 | 2011-12-30 | Array Biopharma Inc | Pirimidil ciklopentani kot inhibitorji AKT-protein-kinaze |
US9409886B2 (en) | 2007-07-05 | 2016-08-09 | Array Biopharma Inc. | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
US8846683B2 (en) | 2007-07-05 | 2014-09-30 | Array Biopharma, Inc. | Pyrimidyl cyclopentanes as Akt protein kinase inhibitors |
WO2009015254A1 (en) | 2007-07-25 | 2009-01-29 | Bristol-Myers Squibb Company | Triazine kinase inhibitors |
CA2694499A1 (en) * | 2007-07-31 | 2009-02-05 | Vertex Pharmaceuticals Incorporated | Process for preparing 5-fluoro-1h-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof |
TW200906818A (en) * | 2007-07-31 | 2009-02-16 | Astrazeneca Ab | Chemical compounds |
US8404856B2 (en) | 2007-11-20 | 2013-03-26 | Merck Sharp & Dohme Corp. | Non-nucleoside reverse transcriptase inhibitors |
MX364936B (es) * | 2007-12-07 | 2019-05-15 | Vertex Pharma | Procesos para producir acidos cicloalquilcarboxamido-piridin benzoicos. |
PL2225230T3 (pl) | 2007-12-07 | 2017-08-31 | Vertex Pharmaceuticals Incorporated | Stałe postacie kwasu 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-ilo)cyklopropanokarboksyamido)-3-metylopirydyn-2-ylo)benzoesowego |
JP2011032169A (ja) * | 2007-12-11 | 2011-02-17 | Genecare Research Institute Co Ltd | 4−アミノピリミジン誘導体および該化合物を含有する医薬組成物 |
EP2224929B1 (en) | 2007-12-17 | 2016-05-04 | Janssen Pharmaceutica, N.V. | Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of trpv1 |
EP2240483B8 (en) | 2008-01-09 | 2013-04-03 | Array Biopharma, Inc. | Pyrimidyl cyclopentanes as akt protein kinase inhibitors |
US8329709B2 (en) * | 2008-01-09 | 2012-12-11 | Genentech, Inc. | 5H-cyclopenta[D]pyrimidines as AKT protein kinase inhibitors |
US8716483B2 (en) | 2008-02-21 | 2014-05-06 | Merck Sharp & Dohme Corp. | Compounds that are ERK inhibitors |
ES2647531T3 (es) | 2008-02-28 | 2017-12-22 | Vertex Pharmaceuticals Incorporated | Derivados de heteroarilo como moduladores de CFTR |
EP2262498A2 (en) * | 2008-03-10 | 2010-12-22 | Vertex Pharmceuticals Incorporated | Pyrimidines and pyridines useful as inhibitors of protein kinases |
CL2009000904A1 (es) * | 2008-04-21 | 2010-04-30 | Shionogi & Co | Compuestos derivados de ciclohexil sulfonamidas que tienen actividad antagonista en el receptor npy y5, composicion farmaceutica y formulacion farmaceutica que los comprende. |
US8158656B2 (en) * | 2008-05-16 | 2012-04-17 | Shenzhen Chipscreen Biosciences Ltd. | 2-indolinone derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors |
MX2010012703A (es) | 2008-05-21 | 2010-12-21 | Ariad Pharma Inc | Derivados fosforosos como inhibidores de cinasa. |
UY31885A (es) * | 2008-06-11 | 2010-01-29 | Astrazeneca Ab | Derivados de las 1, 3, 5-triazina-2, 4-diaminas-6-sustituidas-n-sustituidas y sales farmacéuticamente aceptables de los mismos, composiciones y aplicaciones. |
PE20110061A1 (es) | 2008-06-12 | 2011-01-31 | Janssen Pharmaceutica Nv | Derivados de diamino-piridina, pirimidina y piridazina como moduladores del receptor h4 de histamina |
AU2009267161B2 (en) * | 2008-07-03 | 2014-11-06 | Merck Patent Gmbh | Naphthyridininones as Aurora kinase inhibitors |
US8536187B2 (en) | 2008-07-03 | 2013-09-17 | Gilead Sciences, Inc. | 2,4,6-trisubstituted pyrido(3,2-d)pyrimidines useful for treating viral infections |
AR073354A1 (es) * | 2008-07-31 | 2010-11-03 | Genentech Inc | Compuestos de pirimidina, composiciones farmaceuticas y su uso en el tratamiento del cancer. |
WO2010019392A1 (en) * | 2008-08-13 | 2010-02-18 | Merck Sharp & Dohme Corp. | Purine derivatives for treatment of alzheimer's disease |
WO2010027921A1 (en) * | 2008-09-03 | 2010-03-11 | Vertex Pharmaceuticals Incorporated | Co-crystals and pharmaceutical formulations comprising the same |
WO2010031056A2 (en) | 2008-09-15 | 2010-03-18 | The Regents Of The University Of California | Methods and compositions for modulating ire1, src, and abl activity |
RU2011116928A (ru) * | 2008-09-30 | 2012-11-20 | Астразенека Аб (Se) | Гетероциклические ингибиторы jак киназы |
CA2744343A1 (en) * | 2008-11-19 | 2010-05-27 | Renovis, Inc. | 6, 7 -dihydro- 5h- pyrrolo [3, 4-d] pyrimidin-4-yl] -quinolin-3 -ylamine compounds useful as faah modulators and uses thereof |
KR101048448B1 (ko) | 2008-11-21 | 2011-07-11 | 한국화학연구원 | 신규 피라졸로[4,3-b]피리딘 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 약학적 조성물 |
EP3006031A1 (en) | 2009-02-05 | 2016-04-13 | Takeda Pharmaceutical Company Limited | Pyridazinone compounds |
US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
TWI476192B (zh) * | 2009-02-27 | 2015-03-11 | Ambit Biosciences Corp | Jak激酶調節化合物及其使用方法 |
EP2406236A4 (en) * | 2009-03-09 | 2013-07-24 | Surface Logix Inc | INHIBITORS OF RHO KINASE |
WO2010111050A1 (en) * | 2009-03-23 | 2010-09-30 | Banyu Pharmaceutical Co., Ltd. | Novel aminopyridine derivatives having aurora a selective inhibitory action |
US8263632B2 (en) * | 2009-03-24 | 2012-09-11 | Vertex Pharmaceuticals Incoporated | Aminopyridine derivatives having Aurora A selective inhibitory action |
CA2755953A1 (en) * | 2009-03-24 | 2010-09-30 | Vertex Pharmaceuticals Incorporated | Novel aminopyridine derivatives having aurora a selective inhibitory action |
US8211901B2 (en) | 2009-05-22 | 2012-07-03 | Shenzhen Chipscreen Biosciences Ltd. | Naphthamide derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors |
CN101906076B (zh) | 2009-06-04 | 2013-03-13 | 深圳微芯生物科技有限责任公司 | 作为蛋白激酶抑制剂和组蛋白去乙酰化酶抑制剂的萘酰胺衍生物、其制备方法及应用 |
CN105175409A (zh) * | 2009-06-08 | 2015-12-23 | 南特生物科学公司 | 三嗪衍生物及其治疗应用 |
JP5785940B2 (ja) * | 2009-06-09 | 2015-09-30 | アブラクシス バイオサイエンス, エルエルシー | トリアジン誘導体類及びそれらの治療応用 |
CA2765050A1 (en) * | 2009-06-09 | 2010-12-16 | California Capital Equity, Llc | Ureidophenyl substituted triazine derivatives and their therapeutical applications |
CN102480961A (zh) * | 2009-06-24 | 2012-05-30 | 健泰科生物技术公司 | 与含氧杂环稠合的嘧啶化合物、组合物和使用方法 |
US8637525B2 (en) | 2009-07-31 | 2014-01-28 | Bristol-Myers Squibb Company | Compounds for the reduction of beta-amyloid production |
TWI468402B (zh) * | 2009-07-31 | 2015-01-11 | 必治妥美雅史谷比公司 | 降低β-類澱粉生成之化合物 |
US20110053916A1 (en) | 2009-08-14 | 2011-03-03 | Vertex Pharmaceuticals Incorporated | Pyrimidine compounds as tuberculosis inhibitors |
CN102020657A (zh) * | 2009-09-11 | 2011-04-20 | 上海艾力斯医药科技有限公司 | 稠合杂芳基衍生物、制备方法及其应用 |
MX2012005463A (es) | 2009-11-12 | 2012-09-12 | Hoffmann La Roche | Compuestos de purina n/9 sustituida, composiciones y metodos de uso. |
JP5572715B2 (ja) * | 2009-11-12 | 2014-08-13 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | N−7置換プリン及びピラゾロピリミジン化合物、組成物及び使用方法 |
EP2533639A4 (en) * | 2010-02-11 | 2013-08-21 | Univ Vanderbilt | COMPOUNDS OF PYRAZOLOPYRIDINE, PYRAZOLOPYRAZINE, PYRAZOLOPYRIMIDINE, PYRAZOLOTHIOPHENE AND PYRAZOLOTHIAZOLE AS ALLOSTERIC POTENTIALIZERS OF METABOTROPIC GLUTAMATE RECEPTOR SUBTYPE 4 (MGLUR4), COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL DYSFUNCTIONS |
NZ602838A (en) | 2010-04-07 | 2015-06-26 | Vertex Pharma | Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid and administration thereof |
AU2011254550B2 (en) | 2010-05-21 | 2013-11-07 | Noviga Research Ab | Novel pyrimidine derivatives |
JP5713367B2 (ja) | 2010-06-04 | 2015-05-07 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Lrrk2モジュレーターとしてのアミノピリミジン誘導体 |
US20110319409A1 (en) * | 2010-06-23 | 2011-12-29 | Cox Christopher D | 7-aza-quinazoline pde10 inhibitors |
CN103298805A (zh) | 2010-09-01 | 2013-09-11 | 埃姆比特生物科学公司 | 喹唑啉化合物及其使用方法 |
CA2810954A1 (en) | 2010-09-27 | 2012-04-05 | Abbott Gmbh & Co. Kg | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |
WO2012059932A1 (en) | 2010-11-01 | 2012-05-10 | Aurigene Discovery Technologies Limited | 2, 4 -diaminopyrimidine derivatives as protein kinase inhibitors |
WO2012060847A1 (en) | 2010-11-07 | 2012-05-10 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
CA3017869C (en) | 2010-11-10 | 2021-07-27 | Genentech, Inc. | Pyrazole aminopyrimidine derivatives as lrrk2 modulators |
ES2650744T3 (es) | 2010-12-14 | 2018-01-22 | Electrophoretics Limited | Inhibidores de la caseína quinasa 1 delta (CK1delta) |
CN103270026A (zh) | 2010-12-21 | 2013-08-28 | 诺瓦提斯公司 | 作为vps34抑制剂的联-杂芳基化合物 |
US9090592B2 (en) | 2010-12-30 | 2015-07-28 | AbbVie Deutschland GmbH & Co. KG | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |
WO2012101654A2 (en) * | 2011-01-25 | 2012-08-02 | Sphaera Pharma Pvt. Ltd | Novel triazine compounds |
JP5886411B2 (ja) | 2011-03-24 | 2016-03-16 | ノビガ・リサーチ・エービーNoviga Research AB | 新規のピリミジン誘導体 |
MX2013011333A (es) | 2011-04-01 | 2014-04-16 | Genentech Inc | Combinaciones de compuestos inhibidores de akt y mek, y metodos de uso. |
ES2620644T3 (es) | 2011-04-01 | 2017-06-29 | Genentech, Inc. | Combinaciones de compuestos inhibidores de AKT y agentes quimioterapéuticos, y métodos de uso |
RU2477723C2 (ru) | 2011-06-16 | 2013-03-20 | Общество С Ограниченной Ответственностью "Фьюжн Фарма" | Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе |
CN103930422A (zh) | 2011-07-19 | 2014-07-16 | 无限药品股份有限公司 | 杂环化合物及其用途 |
US8846656B2 (en) | 2011-07-22 | 2014-09-30 | Novartis Ag | Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators |
RU2014109897A (ru) | 2011-08-25 | 2015-09-27 | Ф.Хоффманн-Ля Рош Аг | Ингибиторы серин/треонин киназы рак1 |
IN2014CN02646A (no) | 2011-09-14 | 2015-08-07 | Samumed Llc | |
CA2847540C (en) | 2011-09-22 | 2016-05-17 | Pfizer Inc. | Pyrrolopyrimidine and purine derivatives |
MX342326B (es) | 2011-09-27 | 2016-09-26 | Novartis Ag | 3-pirimidin-4-il-oxazolidin-2-onas como inhibidoras de idh mutante. |
US8815877B2 (en) | 2011-12-22 | 2014-08-26 | Genentech, Inc. | Serine/threonine kinase inhibitors |
UY34632A (es) | 2012-02-24 | 2013-05-31 | Novartis Ag | Compuestos de oxazolidin- 2- ona y usos de los mismos |
RU2014141674A (ru) * | 2012-03-16 | 2016-05-10 | Аксикин Фармасьютикалз, Инк. | 3,5-диаминопиразоловые ингибиторы киназы |
AU2013237226A1 (en) * | 2012-03-19 | 2014-10-09 | Emory University | Quinazoline compounds and their use in therapy |
US20130303519A1 (en) | 2012-03-20 | 2013-11-14 | Millennium Pharmaceuticals, Inc. | Methods of treating cancer using aurora kinase inhibitors |
PH12017500997A1 (en) | 2012-04-04 | 2018-02-19 | Samumed Llc | Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof |
RS61664B1 (sr) | 2012-04-24 | 2021-04-29 | Vertex Pharma | Inhibitori dna-pk |
CN106279202A (zh) * | 2012-05-03 | 2017-01-04 | 霍夫曼-拉罗奇有限公司 | 作为lrrk2调节剂用于治疗帕金森病的吡唑氨基嘧啶衍生物 |
CN106220615A (zh) * | 2012-05-03 | 2016-12-14 | 霍夫曼-拉罗奇有限公司 | 作为lrrk2调节剂的吡唑氨基嘧啶衍生物 |
SG10201610869TA (en) | 2012-06-26 | 2017-02-27 | Del Mar Pharmaceuticals | Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalacti |
CA2886495C (en) * | 2012-09-28 | 2023-09-19 | Ignyta, Inc. | Azaquinazoline inhibitors of atypical protein kinase c |
JO3470B1 (ar) | 2012-10-08 | 2020-07-05 | Merck Sharp & Dohme | مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv |
ES2644758T3 (es) | 2012-10-16 | 2017-11-30 | Tolero Pharmaceuticals, Inc. | Moduladores de PKM2 y métodos para su uso |
US9296733B2 (en) | 2012-11-12 | 2016-03-29 | Novartis Ag | Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases |
KR20150087850A (ko) * | 2012-11-20 | 2015-07-30 | 제넨테크, 인크. | Egfr 돌연변이체를 함유하는 t790m의 억제제로서의 아미노피리미딘 화합물 |
KR102275676B1 (ko) | 2012-11-21 | 2021-07-12 | 피티씨 테라퓨틱스, 인크. | 치환된 리버스 피리미딘 bmi-1 저해제 |
CN103012428A (zh) | 2013-01-08 | 2013-04-03 | 中国药科大学 | 4-(五元杂环并嘧啶/吡啶取代)氨基-1H-3-吡唑甲酰胺类CDK/Aurora双重抑制剂及其用途 |
MX370487B (es) | 2013-01-08 | 2019-12-16 | Samumed Llc | Inhibidores de 3-(benzo-imidazol-2-il)-indazol de la senda de señalización de wnt y usos terapéuticos de los mismos. |
TWI644899B (zh) | 2013-02-04 | 2018-12-21 | 健生藥品公司 | Flap調節劑 |
EP3495359A1 (en) * | 2013-02-04 | 2019-06-12 | Janssen Pharmaceutica NV | Flap modulators |
EP2769722A1 (en) * | 2013-02-22 | 2014-08-27 | Ruprecht-Karls-Universität Heidelberg | Compounds for use in inhibiting HIV capsid assembly |
JO3377B1 (ar) * | 2013-03-11 | 2019-03-13 | Takeda Pharmaceuticals Co | مشتقات بيريدينيل وبيريدينيل مندمج |
RS58374B1 (sr) | 2013-03-12 | 2019-03-29 | Vertex Pharma | Inhibitori dnk-pk |
MX355945B (es) | 2013-03-14 | 2018-05-07 | Novartis Ag | 3-pirimidin-4-il-oxazolidin-2-onas como inhibidoras de idh mutante. |
CN105209042B (zh) | 2013-03-22 | 2019-03-08 | 米伦纽姆医药公司 | 催化性mtorc 1/2抑制剂与选择性极光a激酶抑制剂的组合 |
WO2015013581A1 (en) | 2013-07-26 | 2015-01-29 | Update Pharma Inc. | Combinatorial methods to improve the therapeutic benefit of bisantrene |
KR102232595B1 (ko) | 2013-08-30 | 2021-03-26 | 피티씨 테라퓨틱스, 인크. | 치환된 피리미딘 bmi-1 저해제 |
WO2015028848A1 (en) * | 2013-09-02 | 2015-03-05 | Piramal Enterprises Limited | Bicyclic heterocyclic compounds as multi-kinase inhibitors |
LT3052096T (lt) | 2013-10-03 | 2018-04-10 | Kura Oncology, Inc. | Erk inhibitoriai ir jų panaudojimo būdai |
EP3055301B1 (en) * | 2013-10-07 | 2019-11-20 | Kadmon Corporation, LLC | (2-(5-isoindolin-2-yl)pyrimidin-4-yl)-amine derivatives as rho kinase inhibitors for treating autoimmune diseases |
EP3057953B1 (en) | 2013-10-17 | 2018-08-15 | Vertex Pharmaceuticals Incorporated | Co-crystals of (s)-n-methyl-8-(1-((2'-methyl-[4,5'-bipyrimidin]-6-yl)amino)propan-2-yl)quinoline-4-carboxamide and deuterated derivatives thereof as dna-pk inhibitors |
MX2016006118A (es) | 2013-11-12 | 2016-07-21 | Vertex Pharma | Proceso para preparar composiciones farmaceuticas para el tratamiento de enfermedades mediadas por regulador de la conductancia transmembrana de la fibrosis quistica (cftr). |
US10584115B2 (en) | 2013-11-21 | 2020-03-10 | Ptc Therapeutics, Inc. | Substituted pyridine and pyrazine BMI-1 inhibitors |
US9975878B2 (en) | 2013-11-21 | 2018-05-22 | Ptc Therapeutics, Inc. | Substituted triazine BMI-1 inhibitors |
UA115388C2 (uk) | 2013-11-21 | 2017-10-25 | Пфайзер Інк. | 2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань |
CN104672250B (zh) * | 2013-11-29 | 2017-11-07 | 广东东阳光药业有限公司 | 取代的杂芳基化合物及其组合物和用途 |
ES2813875T3 (es) | 2014-01-01 | 2021-03-25 | Medivation Tech Llc | Compuestos y procedimientos de uso |
WO2015112739A1 (en) * | 2014-01-22 | 2015-07-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compounds and method for treating parp1-deficient cancers |
CN104926795B (zh) * | 2014-03-17 | 2017-11-10 | 广东东阳光药业有限公司 | 取代的杂芳基化合物及其组合物和用途 |
TWI675836B (zh) * | 2014-03-25 | 2019-11-01 | 美商伊格尼塔公司 | 非典型蛋白質激酶c之氮雜喹唑啉抑制劑 |
WO2015155738A2 (en) | 2014-04-09 | 2015-10-15 | Christopher Rudd | Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity |
CN105367555B (zh) * | 2014-08-07 | 2019-06-25 | 广东东阳光药业有限公司 | 取代的杂芳基化合物及其组合物和用途 |
WO2016040180A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof |
WO2016040181A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof |
WO2016040190A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof |
WO2016040185A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof |
WO2016040184A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof |
WO2016040193A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof |
US10302602B2 (en) | 2014-11-18 | 2019-05-28 | Vertex Pharmaceuticals Incorporated | Process of conducting high throughput testing high performance liquid chromatography |
TWI704151B (zh) * | 2014-12-22 | 2020-09-11 | 美商美國禮來大藥廠 | Erk抑制劑 |
ES2700200T3 (es) * | 2014-12-22 | 2019-02-14 | Lilly Co Eli | Inhibidores de ERK |
US10227343B2 (en) | 2015-01-30 | 2019-03-12 | Vanderbilt University | Isoquiniline and napthalene-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
EP3070084A1 (en) * | 2015-03-18 | 2016-09-21 | Rottapharm Biotech S.r.l. | New fyn kinase inhibitors |
AU2016247858B2 (en) | 2015-04-17 | 2020-10-15 | Ludwig Institute For Cancer Research Ltd. | PLK4 inhibitors |
WO2016197009A1 (en) | 2015-06-05 | 2016-12-08 | Vertex Pharmaceuticals Incorporated | Triazoles for the treatment of demyelinating diseases |
WO2017023987A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof |
US10166218B2 (en) | 2015-08-03 | 2019-01-01 | Samumed, Llc | 3-(1H-indol-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof |
US10195185B2 (en) | 2015-08-03 | 2019-02-05 | Samumed, Llc | 3-(1H-imidazo[4,5-C]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof |
US10519169B2 (en) | 2015-08-03 | 2019-12-31 | Samumed, Llc | 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof |
US10604512B2 (en) | 2015-08-03 | 2020-03-31 | Samumed, Llc | 3-(1H-indol-2-yl)-1H-indazoles and therapeutic uses thereof |
US10392383B2 (en) | 2015-08-03 | 2019-08-27 | Samumed, Llc | 3-(1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
WO2017024004A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
WO2017023984A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof |
WO2017024015A1 (en) * | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
WO2017024003A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc | 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
WO2017023996A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof |
WO2017024021A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc | 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof |
US10188634B2 (en) | 2015-08-03 | 2019-01-29 | Samumed, Llc | 3-(3H-imidazo[4,5-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof |
US10383861B2 (en) | 2015-08-03 | 2019-08-20 | Sammumed, LLC | 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof |
WO2017023993A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-indol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
US10285982B2 (en) | 2015-08-03 | 2019-05-14 | Samumed, Llc | 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof |
US10463651B2 (en) | 2015-08-03 | 2019-11-05 | Samumed, Llc | 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-indazoles and therapeutic uses thereof |
WO2017079759A1 (en) | 2015-11-06 | 2017-05-11 | Samumed, Llc | 2-(1h-indazol-3-yl)-3h-imidazo[4,5-c]pyridines and their anti-inflammatory uses thereof |
GB201604647D0 (en) * | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
HRP20221446T1 (hr) | 2016-06-01 | 2023-01-06 | Biosplice Therapeutics, Inc. | Postupci za pripremu n-(5-(3-(7-(3-fluorofenil)-3h-imidazo[4,5-c]piridin-2-il)-1h-indazol-5-il)piridin-3-il)-3-metilbutanamida |
TW201815418A (zh) | 2016-09-27 | 2018-05-01 | Vertex Pharma | 使用dna破壞劑及dna-pk抑制劑之組合治療癌症的方法 |
BR112019008061A2 (pt) | 2016-10-21 | 2019-09-17 | Samumed Llc | métodos de uso de indazol-3-carboxamidas e seu uso como inibidores da via de sinalização de wnt/b-catenina |
WO2018085171A1 (en) | 2016-11-01 | 2018-05-11 | Merck Sharp & Dohme Corp. | Substituted bicyclic heteroaryl allosteric modulators of nicotinic acetylcholine receptors |
JP2019533702A (ja) | 2016-11-07 | 2019-11-21 | サミュメッド リミテッド ライアビリティ カンパニー | 単回用量の調整済み注射用製剤 |
IT201700047189A1 (it) * | 2017-05-02 | 2018-11-02 | Fondazione St Italiano Tecnologia | Composti e composizioni per il trattamento di cancro, disordini della retina e cardiomiopatie |
AR112027A1 (es) | 2017-06-15 | 2019-09-11 | Biocryst Pharm Inc | Inhibidores de alk 2 quinasa que contienen imidazol |
CA3063616A1 (en) | 2017-06-30 | 2019-12-06 | Beijing Tide Pharmaceutical Co., Ltd. | Rho-associated protein kinase inhibitor, pharmaceutical composition comprising same, and preparation method and use thereof |
WO2019000682A1 (zh) * | 2017-06-30 | 2019-01-03 | 北京泰德制药股份有限公司 | Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途 |
JP7039802B2 (ja) | 2017-06-30 | 2022-03-23 | ベイジン タイド ファーマシューティカル カンパニー リミテッド | Rho-関連プロテインキナーゼ阻害剤、rho-関連プロテインキナーゼ阻害剤を含む医薬組成物、当該医薬組成物の調製方法及び使用 |
CN109384774B (zh) * | 2017-08-11 | 2023-02-17 | 中国科学院上海药物研究所 | 一类多取代的吡嗪/三嗪酰胺类化合物及其制备方法和应用 |
CA3074034A1 (en) | 2017-10-27 | 2019-05-02 | Theravance Biopharma R&D Ip, Llc | Pyrimidine compound as jak kinase inhibitor |
GB201801226D0 (en) | 2018-01-25 | 2018-03-14 | Redx Pharma Plc | Modulators of Rho-associated protein kinase |
US12030857B2 (en) * | 2018-06-25 | 2024-07-09 | Kadmon Corporation, Llc | Glucose uptake inhibitors |
EP3836932A2 (en) | 2018-08-17 | 2021-06-23 | PTC Therapeutics, Inc. | Method for treating pancreatic cancer |
WO2020045941A1 (ko) * | 2018-08-27 | 2020-03-05 | 주식회사 대웅제약 | 신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물 |
KR102328682B1 (ko) * | 2018-08-27 | 2021-11-18 | 주식회사 대웅제약 | 신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물 |
US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
PL3902803T3 (pl) * | 2018-12-27 | 2023-05-22 | Les Laboratoires Servier | Aza-heterobicykliczne inhibitory mat2a i sposoby zastosowania do leczenia nowotworu |
WO2020142748A1 (en) | 2019-01-03 | 2020-07-09 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Methods and materials for increasing transcription factor eb polypeptide levels |
US20220133740A1 (en) | 2019-02-08 | 2022-05-05 | Frequency Therapeutics, Inc. | Valproic acid compounds and wnt agonists for treating ear disorders |
WO2020168197A1 (en) | 2019-02-15 | 2020-08-20 | Incyte Corporation | Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors |
TW202100520A (zh) | 2019-03-05 | 2021-01-01 | 美商英塞特公司 | 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物 |
EP3941463A1 (en) | 2019-03-22 | 2022-01-26 | Sumitomo Dainippon Pharma Oncology, Inc. | Compositions comprising pkm2 modulators and methods of treatment using the same |
CA3134405A1 (en) | 2019-03-28 | 2020-10-01 | Jiangsu Hengrui Medicine Co., Ltd. | Thienoheterocyclic derivative, preparation method therefor and medical use thereof |
KR20210146956A (ko) | 2019-03-29 | 2021-12-06 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | 피롤로헤테로고리형 유도체, 이의 제조 방법, 및 의약에서 이의 응용 |
US11919904B2 (en) | 2019-03-29 | 2024-03-05 | Incyte Corporation | Sulfonylamide compounds as CDK2 inhibitors |
CN109826608A (zh) * | 2019-04-08 | 2019-05-31 | 中国科学院地质与地球物理研究所 | 一种分段压裂装置 |
TW202106681A (zh) | 2019-04-24 | 2021-02-16 | 美商施萬生物製藥研發Ip有限責任公司 | 用於治療皮膚疾病之嘧啶jak抑制劑 |
PL3958969T3 (pl) | 2019-04-24 | 2024-05-20 | Theravance Biopharma R&D Ip, Llc | Estrowe i węglanowe związki pirymidynowe jako inhibitory kinaz |
US11440914B2 (en) | 2019-05-01 | 2022-09-13 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
WO2020223558A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | Tricyclic amine compounds as cdk2 inhibitors |
CN113825757B (zh) | 2019-05-24 | 2023-10-20 | 江苏恒瑞医药股份有限公司 | 取代的稠合双环类衍生物、其制备方法及其在医药上的应用 |
WO2020243519A1 (en) * | 2019-05-29 | 2020-12-03 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
EP4013750A1 (en) | 2019-08-14 | 2022-06-22 | Incyte Corporation | Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors |
US20220289692A1 (en) * | 2019-09-06 | 2022-09-15 | Inflazome Limited | Nlrp3 inhibitors |
KR20220079597A (ko) * | 2019-10-02 | 2022-06-13 | 톨레모 테라퓨틱스 아게 | 헤테로사이클릭 유도체, 약학 조성물 및 암의 치료 또는 개선에서 그들의 용도 |
WO2021072232A1 (en) | 2019-10-11 | 2021-04-15 | Incyte Corporation | Bicyclic amines as cdk2 inhibitors |
AU2021226411A1 (en) * | 2020-02-26 | 2022-09-22 | Jaguahr Therapeutics Pte Ltd | Pyridopyrimidine derivatives useful in modulation of AhR signalling |
MX2022011826A (es) * | 2020-03-27 | 2022-10-18 | Dong A St Co Ltd | Derivados de aminopirimidina y su uso como moduladores del receptor de hidrocarburos de arilo. |
KR20230051500A (ko) | 2020-07-15 | 2023-04-18 | 키에시 파르마슈티시 엣스. 피. 에이. | Alk5 억제제로서 피리다진일 아미노 유도체 |
WO2022032484A1 (zh) * | 2020-08-11 | 2022-02-17 | 北京诺诚健华医药科技有限公司 | 哒嗪-3-甲酰胺类化合物、其制备方法及其在医药学上的应用 |
CN114149410A (zh) * | 2020-09-07 | 2022-03-08 | 四川科伦博泰生物医药股份有限公司 | 吡啶并环类化合物及其制备方法和用途 |
WO2022068860A1 (zh) | 2020-09-29 | 2022-04-07 | 江苏恒瑞医药股份有限公司 | 一种吡咯并杂环类衍生物的晶型及其制备方法 |
WO2022107919A1 (ko) * | 2020-11-19 | 2022-05-27 | 주식회사 보로노이 | N을 포함하는 헤테로아릴 유도체 및 이를 유효성분으로 포함하는 단백질 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물 |
US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
US11932648B2 (en) | 2021-06-28 | 2024-03-19 | Blueprint Medicines Corporation | CDK2 inhibitors |
AR127108A1 (es) | 2021-09-21 | 2023-12-20 | Chiesi Farm Spa | Derivados de amino piridazinilo como inhibidores de alk5 |
CN116023380B (zh) * | 2021-10-26 | 2024-01-23 | 沈阳药科大学 | 一类吡唑并嘧啶衍生物及制备方法和应用 |
US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
AU2023207775A1 (en) | 2022-01-11 | 2024-08-22 | Chiesi Farmaceutici S.P.A. | Pyridazinyl amino derivatives as alk5 inhibitors |
Family Cites Families (120)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3133081A (en) | 1964-05-12 | J-aminoindazole derivatives | ||
US665330A (en) * | 1899-12-18 | 1901-01-01 | Antoine J Langelier | Machine for making blanks for sewing-machine needles or similar articles. |
US3935183A (en) * | 1970-01-26 | 1976-01-27 | Imperial Chemical Industries Limited | Indazole-azo phenyl compounds |
BE754242A (fr) * | 1970-07-15 | 1971-02-01 | Geigy Ag J R | Diamino-s-triazines et dinitro-s-triazines |
US3998951A (en) * | 1974-03-13 | 1976-12-21 | Fmc Corporation | Substituted 2-arylquinazolines as fungicides |
DE2458965C3 (de) * | 1974-12-13 | 1979-10-11 | Bayer Ag, 5090 Leverkusen | 3-Amino-indazol-N-carbonsäure-Derivate, Verfahren zu ihrer Herstellung sowie sie enthaltende Arzneimittel |
MA18829A1 (fr) | 1979-05-18 | 1980-12-31 | Ciba Geigy Ag | Derives de la pyrimidine,procedes pour leur preparation,compositions pharmaceutiques contenant ces composes et leur utilisation therapeutique |
DOP1981004033A (es) * | 1980-12-23 | 1990-12-29 | Ciba Geigy Ag | Procedimiento para proteger plantas de cultivo de la accion fitotoxica de herbicidas. |
SE8102194L (sv) * | 1981-04-06 | 1982-10-07 | Pharmacia Ab | Terapeutiskt aktiv organisk forening och farmaceutisk beredning innehallande denna |
SE8102193L (sv) * | 1981-04-06 | 1982-10-07 | Pharmacia Ab | Terapeutiskt aktiv organisk forening och dess anvendning |
JPS58124773A (ja) * | 1982-01-20 | 1983-07-25 | Mitsui Toatsu Chem Inc | 5−メチルチオピリミジン誘導体とその製造法と農園芸用殺菌剤 |
EP0136976A3 (de) * | 1983-08-23 | 1985-05-15 | Ciba-Geigy Ag | Verwendung von Phenylpyrimidinen als Pflanzenregulatoren |
DE3725638A1 (de) | 1987-08-03 | 1989-02-16 | Bayer Ag | Neue aryloxy (bzw. thio)aminopyrimidine |
JPH0532662A (ja) | 1990-11-09 | 1993-02-09 | Nissan Chem Ind Ltd | 置換ピラゾール誘導体および農園芸用殺菌剤 |
US5710158A (en) | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
US5597920A (en) | 1992-04-30 | 1997-01-28 | Neurogen Corporation | Gabaa receptor subtypes and methods for screening drug compounds using imidazoquinoxalines and pyrrolopyrimidines to bind to gabaa receptor subtypes |
JP2657760B2 (ja) * | 1992-07-15 | 1997-09-24 | 小野薬品工業株式会社 | 4−アミノキナゾリン誘導体およびそれを含有する医薬品 |
AU693114B2 (en) | 1993-10-01 | 1998-06-25 | Novartis Ag | Pharmacologically active pyrimidineamine derivatives and processes for the preparation thereof |
WO1996014843A2 (en) | 1994-11-10 | 1996-05-23 | Cor Therapeutics, Inc. | Pharmaceutical pyrazole compositions useful as inhibitors of protein kinases |
US5658902A (en) * | 1994-12-22 | 1997-08-19 | Warner-Lambert Company | Quinazolines as inhibitors of endothelin converting enzyme |
IL117659A (en) | 1995-04-13 | 2000-12-06 | Dainippon Pharmaceutical Co | Substituted 2-phenyl pyrimidino amino acetamide derivative process for preparing the same and a pharmaceutical composition containing same |
CA2230896A1 (en) | 1995-09-01 | 1997-03-13 | Signal Pharmaceuticals, Inc. | Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions |
GB9523675D0 (en) | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
WO1997020820A1 (en) | 1995-12-01 | 1997-06-12 | Novartis Ag | Heteroaryl compounds |
US6716575B2 (en) * | 1995-12-18 | 2004-04-06 | Sugen, Inc. | Diagnosis and treatment of AUR1 and/or AUR2 related disorders |
PT912559E (pt) | 1996-07-13 | 2003-03-31 | Glaxo Group Ltd | Compostos heterociclicos fundidos como inibidores de proteina tirosina quinase |
JPH10130150A (ja) * | 1996-09-05 | 1998-05-19 | Dainippon Pharmaceut Co Ltd | 酢酸アミド誘導体からなる医薬 |
GB9619284D0 (en) * | 1996-09-16 | 1996-10-30 | Celltech Therapeutics Ltd | Chemical compounds |
DE69732780T2 (de) | 1996-10-02 | 2006-04-06 | Novartis Ag | Pyrimiderivate und verfahren zu ihrer herstellung |
AU738341B2 (en) | 1996-10-11 | 2001-09-13 | Abbott Gmbh & Co. Kg | Asparate ester inhibitors of interleukin-1beta converting enzyme |
JP4439111B2 (ja) | 1997-10-10 | 2010-03-24 | サイトビア インコーポレイテッド | ジペプチドのアポトーシスインヒビターおよびそれらの使用 |
DE19756388A1 (de) | 1997-12-18 | 1999-06-24 | Hoechst Marion Roussel De Gmbh | Substituierte 2-Aryl-4-amino-chinazoline |
US6267952B1 (en) | 1998-01-09 | 2001-07-31 | Geltex Pharmaceuticals, Inc. | Lipase inhibiting polymers |
JP2000026421A (ja) * | 1998-01-29 | 2000-01-25 | Kumiai Chem Ind Co Ltd | ジアリ―ルスルフィド誘導体及び有害生物防除剤 |
ATE245641T1 (de) | 1998-02-17 | 2003-08-15 | Tularik Inc | Antivirale pyrimidinderivate |
ATE295177T1 (de) | 1998-03-16 | 2005-05-15 | Cytovia Inc | Dipeptid kaspase inhibitoren und deren verwendung |
AR020590A1 (es) | 1998-06-02 | 2002-05-22 | Cadus Pharmaceutical Corp | 7-diazapurina-n-6 sustituida, un metodo para su preparacion, composiciones farmaceuticas que la comprenden |
EP1087963B1 (en) | 1998-06-19 | 2004-08-25 | Chiron Corporation | Inhibitors of glycogen synthase kinase 3 |
CA2339188A1 (en) * | 1998-08-21 | 2000-03-02 | Dupont Pharmaceuticals Company | Isoxazolo¬4,5-d|pyrimidines as crf antagonists |
US6184226B1 (en) * | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
PT1119567E (pt) * | 1998-10-08 | 2005-08-31 | Astrazeneca Ab | Derivados de quinazolina |
GB9828511D0 (en) | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
US6545030B1 (en) * | 1999-01-13 | 2003-04-08 | Warner-Lambert Company | 1-heterocycle substituted diarylamines |
ES2225107T3 (es) | 1999-03-29 | 2005-03-16 | Uutech Limited | Analogos del peptido inhibidor gastrico y su uso para el tratamiento de la diabetes. |
BR0009507A (pt) | 1999-03-30 | 2002-01-15 | Novartis Ag | Derivados de ftalazina para o tratamento de doenças inflamatórias |
AU781849C (en) | 1999-06-17 | 2006-03-02 | Synta Pharmaceuticals Corp. | Inhibitors of IL-12 production |
GB9914258D0 (en) * | 1999-06-18 | 1999-08-18 | Celltech Therapeutics Ltd | Chemical compounds |
JP2001042764A (ja) | 1999-08-04 | 2001-02-16 | Sony Corp | 地図表示装置 |
EP1218369B1 (en) | 1999-08-13 | 2008-07-23 | Vertex Pharmaceuticals Incorporated | INHIBITORS OF c-JUN N-TERMINAL KINASES (JNK) AND OTHER PROTEIN KINASES |
ES2306671T3 (es) | 1999-10-07 | 2008-11-16 | Amgen Inc. | Inhibidores de triazina quinasa. |
AU1047601A (en) | 1999-11-30 | 2001-06-12 | Pfizer Products Inc. | 2,4-diaminopyrimidine compounds useful as immunosuppressants |
AU784878B2 (en) | 1999-12-02 | 2006-07-13 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 A2A and A3 receptors and uses thereof |
MY125768A (en) | 1999-12-15 | 2006-08-30 | Bristol Myers Squibb Co | N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases |
US6376489B1 (en) | 1999-12-23 | 2002-04-23 | Icos Corporation | Cyclic AMP-specific phosphodiesterase inhibitors |
ATE449764T1 (de) | 1999-12-28 | 2009-12-15 | Pharmacopeia Inc | Cytokine, insbesondere tnf-alpha, hemmer |
US20020065270A1 (en) * | 1999-12-28 | 2002-05-30 | Moriarty Kevin Joseph | N-heterocyclic inhibitors of TNF-alpha expression |
TR200103787T1 (tr) | 2000-02-05 | 2002-10-21 | Vertex Pharmaceuticals Incorporated | Hücre-dışı sinyal ayarlı kinazların(ERK) inhibitörü olarak yararlı pirazol bileşimler |
CA2400447C (en) * | 2000-02-17 | 2008-04-22 | Amgen Inc. | Kinase inhibitors |
GB0004890D0 (en) * | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
GB0004887D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
WO2001074768A2 (en) | 2000-04-03 | 2001-10-11 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
WO2001079198A1 (en) | 2000-04-18 | 2001-10-25 | Agouron Pharmaceuticals, Inc. | Pyrazoles for inhibiting protein kinase |
PL360439A1 (en) * | 2000-06-28 | 2004-09-06 | Astrazeneca Ab | Substituted quinazoline derivatives and their use as inhibitors |
PL206255B1 (pl) | 2000-07-21 | 2010-07-30 | Dendreon Corporationdendreon Corporation | Inhibitor proteazy wirusa zapalenia wątroby C, zawierająca go kompozycja farmaceutyczna i zastosowanie inhibitora do wytwarzania leku do leczenia chorób związanych z HCV oraz zastosowanie do wytwarzania kompozycji do stosowania w kombinowanej terapii |
JP2004507526A (ja) | 2000-08-31 | 2004-03-11 | ファイザー・プロダクツ・インク | ピラゾール誘導体及びそのプロテインキナーゼ阻害剤としての使用 |
US6638926B2 (en) | 2000-09-15 | 2003-10-28 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US6613776B2 (en) * | 2000-09-15 | 2003-09-02 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US6660731B2 (en) * | 2000-09-15 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
NZ525016A (en) | 2000-09-15 | 2004-10-29 | Vertex Pharma | Isoxazoles and their use as inhibitors of ERK |
US6610677B2 (en) * | 2000-09-15 | 2003-08-26 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US7473691B2 (en) * | 2000-09-15 | 2009-01-06 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
CA2422488A1 (en) | 2000-09-20 | 2002-03-28 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | 4-amino-quinazolines |
DE10061863A1 (de) * | 2000-12-12 | 2002-06-13 | Basf Ag | Verfahren zur Herstellung von Triethylendiamin (TEDA) |
AU2002228922A1 (en) | 2000-12-12 | 2002-06-24 | Cytovia, Inc. | Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators of caspases and inducers of apoptosis and the use thereof |
US6716851B2 (en) * | 2000-12-12 | 2004-04-06 | Cytovia, Inc. | Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators or caspases and inducers of apoptosis and the use thereof |
CN100436452C (zh) | 2000-12-21 | 2008-11-26 | 沃泰克斯药物股份有限公司 | 可用作蛋白激酶抑制剂的吡唑化合物 |
MY130778A (en) * | 2001-02-09 | 2007-07-31 | Vertex Pharma | Heterocyclic inhibitiors of erk2 and uses thereof |
WO2002079197A1 (en) | 2001-03-29 | 2002-10-10 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
ATE339416T1 (de) * | 2001-04-13 | 2006-10-15 | Vertex Pharma | Inhibitoren von c-jun-n-terminalen-kinasen (jnk) und anderen proteinkinasen |
WO2002085909A1 (en) | 2001-04-20 | 2002-10-31 | Vertex Pharmaceuticals Incorporated | 9-deazaguanine derivatives as inhibitors of gsk-3 |
JP4316893B2 (ja) * | 2001-05-16 | 2009-08-19 | バーテックス ファーマシューティカルズ インコーポレイテッド | Srcおよび他のプロテインキナーゼのインヒビター |
US6762179B2 (en) * | 2001-05-31 | 2004-07-13 | Vertex Pharmaceuticals Incorporated | Thiazole compounds useful as inhibitors of protein kinase |
ATE339418T1 (de) * | 2001-06-01 | 2006-10-15 | Vertex Pharma | Thiazolverbindungen, die sich als inhibitoren von proteinkinasen eignen |
JP4541695B2 (ja) | 2001-06-15 | 2010-09-08 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼインヒビターとしての5−(2−アミノピリミジン−4−イル)ベンズイソキサゾール |
JP4342937B2 (ja) * | 2001-07-03 | 2009-10-14 | バーテックス ファーマシューティカルズ インコーポレイテッド | SrcおよびLckタンパク質キナーゼの阻害剤としてのイソキサゾールピリミジン |
US6916798B2 (en) * | 2001-08-03 | 2005-07-12 | Vertex Pharmaceuticals Incorporated | Inhibitors of GSK-3 and uses thereof |
EP2198867A1 (en) * | 2001-12-07 | 2010-06-23 | Vertex Pharmaceuticals, Inc. | Pyrimidine-based compounds useful as GSK-3 inhibitors |
US20040034037A1 (en) * | 2002-02-06 | 2004-02-19 | Harbeson Scott L. | Heteroaryl compounds useful as inhibitors of GSK-3 |
AU2003225800A1 (en) * | 2002-03-15 | 2003-09-29 | Hayley Binch | Azolylaminoazine as inhibitors of protein kinases |
ATE466580T1 (de) * | 2002-03-15 | 2010-05-15 | Vertex Pharma | Azolylaminoazine als proteinkinasehemmer |
US7863282B2 (en) | 2003-03-14 | 2011-01-04 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
EP1485380B1 (en) * | 2002-03-15 | 2010-05-19 | Vertex Pharmaceuticals Incorporated | Azolylaminoazines as inhibitors of protein kinases |
ES2289279T3 (es) * | 2002-03-15 | 2008-02-01 | Vertex Pharmaceuticals Incorporated | Composiciones utiles como inhibidores de proteinquinasas. |
US20030207873A1 (en) * | 2002-04-10 | 2003-11-06 | Edmund Harrington | Inhibitors of Src and other protein kinases |
WO2003091246A1 (en) * | 2002-04-26 | 2003-11-06 | Vertex Pharmaceuticals Incorporated | Pyrrole derivatives as inhibitors of erk2 and uses thereof |
MY141867A (en) | 2002-06-20 | 2010-07-16 | Vertex Pharma | Substituted pyrimidines useful as protein kinase inhibitors |
US7361665B2 (en) * | 2002-07-09 | 2008-04-22 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases |
CN101037438A (zh) | 2002-08-02 | 2007-09-19 | 沃泰克斯药物股份有限公司 | 用作gsk-3的抑制剂的吡唑组合物 |
CA2506773A1 (en) * | 2002-11-04 | 2004-05-21 | Vertex Pharmaceuticals Incorporated | Heteroaryl-pyramidine derivatives as jak inhibitors |
WO2004072063A1 (en) * | 2003-02-07 | 2004-08-26 | Vertex Pharmaceuticals Incorporated | Heteroaryl substituted pyrolls useful as inhibitors of protein kinases |
EP1605946B1 (en) * | 2003-03-25 | 2008-05-28 | Vertex Pharmaceuticals Incorporated | Thiazoles useful as inhibitors of protein kinases |
WO2004087698A2 (en) * | 2003-03-25 | 2004-10-14 | Vertex Pharmaceuticals Incorporated | Thiazoles useful as inhibitors of protein kinases |
KR20060123164A (ko) | 2003-10-17 | 2006-12-01 | 아스트라제네카 아베 | 암 치료에 사용하기 위한 4-(피라졸-3-일아미노)피리미딘유도체 |
JP4329649B2 (ja) | 2004-08-30 | 2009-09-09 | ソニー株式会社 | 撮像装置及び光学系の駆動方法 |
CA2619517A1 (en) | 2005-08-18 | 2007-02-22 | Michael Mortimore | Pyrazine kinase inhibitors |
WO2007023382A2 (en) | 2005-08-25 | 2007-03-01 | Pfizer Inc. | Pyrimidine amino pyrazole compounds, potent kinase inhibitors |
KR20140025610A (ko) | 2005-09-30 | 2014-03-04 | 미카나 테라퓨틱스, 인크. | 치환된 피라졸 화합물 |
AU2006311830B2 (en) | 2005-11-03 | 2013-03-14 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
DE602006021776D1 (de) | 2005-11-16 | 2011-06-16 | Vertex Pharma | Als kinaseinhibitoren geeignete aminopyrimidine |
AU2007317435A1 (en) | 2006-11-02 | 2008-05-15 | Vertex Pharmaceuticals Incorporated | Aminopyridines and aminopyrimidines useful as inhibitors of protein kinases |
WO2008077086A1 (en) | 2006-12-19 | 2008-06-26 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as inhibitors of protein kinases |
JP5520057B2 (ja) | 2007-03-09 | 2014-06-11 | バーテックス ファーマシューティカルズ インコーポレイテッド | 蛋白キナーゼの阻害剤として有用なアミノピリミジン |
NZ579483A (en) | 2007-03-09 | 2012-07-27 | Vertex Pharma | Aminopyridines useful as inhibitors of protein kinases |
JP5393489B2 (ja) | 2007-03-09 | 2014-01-22 | バーテックス ファーマシューティカルズ インコーポレイテッド | 蛋白キナーゼの阻害剤として有用なアミノピリミジン |
JP2010522194A (ja) | 2007-03-20 | 2010-07-01 | バーテックス ファーマシューティカルズ インコーポレイテッド | キナーゼ阻害薬として有用なアミノピリミジン |
EP2148931A2 (en) | 2007-04-17 | 2010-02-03 | Vertex Pharmaceuticals Incorporated | Drug discovery methods for aurora kinase inhibitors |
WO2008137621A1 (en) | 2007-05-02 | 2008-11-13 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
MX2009011811A (es) | 2007-05-02 | 2010-01-14 | Vertex Pharma | Aminopirimidinas utiles como inhibidores de cinasa. |
CA2685876A1 (en) | 2007-05-02 | 2008-11-13 | Vertex Pharmaceuticals Incorporated | Thiazoles and pyrazoles useful as kinase inhibitors |
EP2164842A2 (en) | 2007-05-24 | 2010-03-24 | Vertex Pharmaceuticals Incorporated | Thiazoles and pyrazoles useful as kinase inhibitors |
-
2001
- 2001-09-14 US US09/953,505 patent/US6638926B2/en not_active Expired - Fee Related
- 2001-09-14 DE DE60119749T patent/DE60119749T2/de not_active Expired - Lifetime
- 2001-09-14 AT AT01971006T patent/ATE294797T1/de active
- 2001-09-14 AT AT01977779T patent/ATE326459T1/de not_active IP Right Cessation
- 2001-09-14 AP APAP/P/2003/002762A patent/AP2003002762A0/en unknown
- 2001-09-14 MX MXPA03002294A patent/MXPA03002294A/es active IP Right Grant
- 2001-09-14 CA CA2422299A patent/CA2422299C/en not_active Expired - Fee Related
- 2001-09-14 JP JP2002526860A patent/JP4170752B2/ja not_active Expired - Fee Related
- 2001-09-14 AT AT01971082T patent/ATE327992T1/de active
- 2001-09-14 KR KR10-2003-7003789A patent/KR20030030005A/ko not_active Application Discontinuation
- 2001-09-14 WO PCT/US2001/028738 patent/WO2002022603A1/en active IP Right Grant
- 2001-09-14 IL IL15478601A patent/IL154786A0/xx unknown
- 2001-09-14 NZ NZ525008A patent/NZ525008A/xx not_active IP Right Cessation
- 2001-09-14 WO PCT/US2001/028792 patent/WO2002022604A1/en active IP Right Grant
- 2001-09-14 DE DE60120194T patent/DE60120194T2/de not_active Expired - Lifetime
- 2001-09-14 DK DK01971082T patent/DK1318997T3/da active
- 2001-09-14 JP JP2002526855A patent/JP4105947B2/ja not_active Expired - Fee Related
- 2001-09-14 WO PCT/US2001/028940 patent/WO2002022607A1/en active IP Right Grant
- 2001-09-14 WO PCT/US2001/028740 patent/WO2002022601A1/en active IP Right Grant
- 2001-09-14 TW TW090122889A patent/TWI303636B/zh not_active IP Right Cessation
- 2001-09-14 WO PCT/US2001/042152 patent/WO2002022608A1/en active IP Right Grant
- 2001-09-14 EP EP01970969A patent/EP1317447B1/en not_active Expired - Lifetime
- 2001-09-14 EP EP01971082A patent/EP1318997B1/en not_active Expired - Lifetime
- 2001-09-14 AU AU2001296871A patent/AU2001296871A1/en not_active Abandoned
- 2001-09-14 PT PT01971006T patent/PT1317448E/pt unknown
- 2001-09-14 CN CNB018174272A patent/CN100355750C/zh not_active Expired - Fee Related
- 2001-09-14 AT AT01977783T patent/ATE363284T1/de not_active IP Right Cessation
- 2001-09-14 HU HU0401819A patent/HUP0401819A3/hu unknown
- 2001-09-14 EP EP01975210A patent/EP1317450B1/en not_active Expired - Lifetime
- 2001-09-14 CN CNA018174329A patent/CN1469875A/zh active Pending
- 2001-09-14 CA CA002422380A patent/CA2422380C/en not_active Expired - Fee Related
- 2001-09-14 PT PT01971082T patent/PT1318997E/pt unknown
- 2001-09-14 US US09/952,878 patent/US7098330B2/en not_active Expired - Fee Related
- 2001-09-14 AU AU2001292670A patent/AU2001292670A1/en not_active Abandoned
- 2001-09-14 AU AU2001290914A patent/AU2001290914A1/en not_active Abandoned
- 2001-09-14 EP EP01977783A patent/EP1318814B1/en not_active Expired - Lifetime
- 2001-09-14 KR KR1020037003787A patent/KR100896664B1/ko not_active IP Right Cessation
- 2001-09-14 CA CA002422354A patent/CA2422354C/en not_active Expired - Fee Related
- 2001-09-14 MX MXPA03002292A patent/MXPA03002292A/es active IP Right Grant
- 2001-09-14 NZ NZ545284A patent/NZ545284A/en not_active IP Right Cessation
- 2001-09-14 AT AT01973050T patent/ATE327991T1/de not_active IP Right Cessation
- 2001-09-14 US US09/953,471 patent/US7115739B2/en not_active Expired - Fee Related
- 2001-09-14 DE DE60128709T patent/DE60128709T2/de not_active Expired - Lifetime
- 2001-09-14 EP EP01971006A patent/EP1317448B2/en not_active Expired - Lifetime
- 2001-09-14 HU HU0302411A patent/HUP0302411A2/hu unknown
- 2001-09-14 JP JP2002526861A patent/JP2004509118A/ja active Pending
- 2001-09-14 IL IL15478401A patent/IL154784A0/xx unknown
- 2001-09-14 AU AU2001294558A patent/AU2001294558A1/en not_active Abandoned
- 2001-09-14 JP JP2002526857A patent/JP4105948B2/ja not_active Expired - Fee Related
- 2001-09-14 AU AU2001290944A patent/AU2001290944A1/en not_active Abandoned
- 2001-09-14 DE DE60120198T patent/DE60120198T2/de not_active Expired - Lifetime
- 2001-09-14 MX MXPA03002293A patent/MXPA03002293A/es active IP Right Grant
- 2001-09-14 HU HU0302173A patent/HUP0302173A2/hu unknown
- 2001-09-14 WO PCT/US2001/028803 patent/WO2002022606A1/en active IP Right Grant
- 2001-09-14 MX MXPA03002295A patent/MXPA03002295A/es active IP Right Grant
- 2001-09-14 IL IL15474701A patent/IL154747A0/xx unknown
- 2001-09-14 AU AU2001296875A patent/AU2001296875A1/en not_active Abandoned
- 2001-09-14 MX MXPA03002289A patent/MXPA03002289A/es active IP Right Grant
- 2001-09-14 US US09/955,601 patent/US6696452B2/en not_active Expired - Fee Related
- 2001-09-14 DE DE60120193T patent/DE60120193T2/de not_active Expired - Lifetime
- 2001-09-14 JP JP2002526858A patent/JP2004509115A/ja active Pending
- 2001-09-14 CA CA002422379A patent/CA2422379C/en not_active Expired - Fee Related
- 2001-09-14 DE DE60110616T patent/DE60110616T3/de not_active Expired - Lifetime
- 2001-09-14 CA CA2422371A patent/CA2422371C/en not_active Expired - Fee Related
- 2001-09-14 PE PE2001000931A patent/PE20020451A1/es not_active Application Discontinuation
- 2001-09-14 MX MXPA03002297A patent/MXPA03002297A/es active IP Right Grant
- 2001-09-14 EP EP01973050A patent/EP1317449B1/en not_active Expired - Lifetime
- 2001-09-14 CA CA2422377A patent/CA2422377C/en not_active Expired - Fee Related
- 2001-09-14 ES ES01970971T patent/ES2266258T3/es not_active Expired - Lifetime
- 2001-09-14 EP EP01970971A patent/EP1317444B1/en not_active Expired - Lifetime
- 2001-09-14 IL IL15481701A patent/IL154817A0/xx unknown
- 2001-09-14 JP JP2002526856A patent/JP4922539B2/ja not_active Expired - Fee Related
- 2001-09-14 CA CA2422367A patent/CA2422367C/en not_active Expired - Fee Related
- 2001-09-14 EP EP01977779A patent/EP1317452B1/en not_active Expired - Lifetime
- 2001-09-14 AT AT01970971T patent/ATE327990T1/de active
- 2001-09-14 CN CNA018174337A patent/CN1473161A/zh active Pending
- 2001-09-14 MX MXPA03002299A patent/MXPA03002299A/es active IP Right Grant
- 2001-09-14 JP JP2002526859A patent/JP4105949B2/ja not_active Expired - Fee Related
- 2001-09-14 PL PL01361676A patent/PL361676A1/xx unknown
- 2001-09-14 ES ES01971082T patent/ES2266259T3/es not_active Expired - Lifetime
- 2001-09-14 KR KR10-2003-7003798A patent/KR20030032035A/ko not_active Application Discontinuation
- 2001-09-14 AT AT01975210T patent/ATE346064T1/de not_active IP Right Cessation
- 2001-09-14 AT AT01970969T patent/ATE326458T1/de not_active IP Right Cessation
- 2001-09-14 NZ NZ525009A patent/NZ525009A/en unknown
- 2001-09-14 MX MXPA03002291A patent/MXPA03002291A/es unknown
- 2001-09-14 CA CA2422378A patent/CA2422378C/en not_active Expired - Fee Related
- 2001-09-14 JP JP2002526854A patent/JP4111824B2/ja not_active Expired - Fee Related
- 2001-09-14 WO PCT/US2001/028793 patent/WO2002022605A1/en active IP Right Grant
- 2001-09-14 WO PCT/US2001/042162 patent/WO2002022602A2/en active IP Right Grant
- 2001-09-14 DE DE60119748T patent/DE60119748T2/de not_active Expired - Lifetime
- 2001-09-14 NZ NZ525014A patent/NZ525014A/en unknown
- 2001-09-14 AU AU2001291013A patent/AU2001291013A1/en not_active Abandoned
- 2001-09-14 AU AU2001290912A patent/AU2001290912A1/en not_active Abandoned
- 2001-09-14 ES ES01971006T patent/ES2242771T5/es not_active Expired - Lifetime
- 2001-09-14 HU HU0302172A patent/HUP0302172A2/hu unknown
- 2001-09-14 DE DE60124744T patent/DE60124744T2/de not_active Expired - Lifetime
- 2001-09-14 KR KR1020037003800A patent/KR100876069B1/ko not_active IP Right Cessation
- 2001-09-14 BR BR0114088-4A patent/BR0114088A/pt not_active IP Right Cessation
-
2003
- 2003-03-04 IL IL154747A patent/IL154747A/en not_active IP Right Cessation
- 2003-03-06 IL IL154784A patent/IL154784A/en not_active IP Right Cessation
- 2003-03-14 NO NO20031191A patent/NO327708B1/no not_active IP Right Cessation
- 2003-03-14 NO NO20031188A patent/NO20031188L/no unknown
- 2003-03-14 NO NO20031189A patent/NO326850B1/no not_active IP Right Cessation
- 2003-03-14 NO NO20031190A patent/NO20031190L/no unknown
- 2003-10-23 US US10/692,355 patent/US7390815B2/en not_active Expired - Fee Related
- 2003-11-14 HK HK03108309A patent/HK1057543A1/xx not_active IP Right Cessation
- 2003-11-20 HK HK03108474A patent/HK1057747A1/xx not_active IP Right Cessation
- 2003-11-21 HK HK03108524A patent/HK1057887A1/xx not_active IP Right Cessation
- 2003-11-25 HK HK03108588A patent/HK1057748A1/xx not_active IP Right Cessation
- 2003-11-26 HK HK03108639A patent/HK1057888A1/xx not_active IP Right Cessation
- 2003-11-27 HK HK03108682A patent/HK1057702A1/xx not_active IP Right Cessation
- 2003-11-28 HK HK03108726A patent/HK1057890A1/xx not_active IP Right Cessation
- 2003-12-15 HK HK03109140A patent/HK1058356A1/xx not_active IP Right Cessation
-
2006
- 2006-07-25 US US11/492,450 patent/US7951820B2/en not_active Expired - Fee Related
-
2008
- 2008-01-25 JP JP2008015681A patent/JP2008115195A/ja active Pending
- 2008-12-03 AU AU2008252044A patent/AU2008252044A1/en not_active Abandoned
-
2011
- 2011-04-26 US US13/094,183 patent/US8633210B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL156389A0 (en) | Pyrazole derivatives and pharmaceutical compositions containing the same | |
IL154747A0 (en) | Pyrazole derivatives and pharmaceutical compositions containing the same | |
IL145757A0 (en) | Pyrazole derivatives and pharmaceutical compositions containing the same | |
IL145756A0 (en) | Pyrazole derivatives and pharmaceutical compositions containing the same | |
IL152451A0 (en) | 2-chloro-2-nitrophenylcarboxamide derivatives and pharmaceutical compositions containing the same | |
HUP0301178A3 (en) | Glucopyranosyloxybenzylbenzene derivatives and pharmaceutical compositions containing the same | |
IL153123A0 (en) | N-ureidoheterocycloalkyl-piperidine derivatives and pharmaceutical compositions containing the same | |
HUP0303108A3 (en) | Substituted pyrazoles and pharmaceutical compositions containing them | |
IL177018A0 (en) | Cyclopropyl-fused pyrrolidine derivatives and pharmaceutical compositions containing the same | |
AU2001290257A1 (en) | Glucopyranosyloxybenzylbenzene derivatives and medicinal compositions containing the same | |
AU2001290257A2 (en) | Glucopyranosyloxybenzylbenzene derivatives and medicinal compositions containing the same | |
IL161616A0 (en) | Indazolypyrrolotriazine derivatives and pharmaceutical compositions containing the same | |
IL164209A0 (en) | Pyrazole derivatives and pharmaceutical compositions containing the same | |
IL166620A0 (en) | Pyrazole derivatives and pharmaceutical compositions containing the same | |
IL152490A0 (en) | Pyridine derivatives and pharmaceutical compositions containing the same | |
IL155196A0 (en) | Benzamide derivatives and pharmaceutical compositions containing the same | |
IL158300A0 (en) | Bisarylimidazol derivatives and pharmaceutical compositions containing the same | |
IL158044A0 (en) | Cyclopropylindole derivatives and pharmaceutical compositions containing the same | |
IL156812A0 (en) | Phthalazinone-piperidino derivatives and pharmaceutical compositions containing the same | |
IL150449A0 (en) | Aniline derivatives and pharmaceutical compositions containing the same | |
IL152846A0 (en) | Pyridazinone derivatives and pharmaceutical compositions containing the same | |
IL156813A0 (en) | Imidazolyl derivatives and pharmaceutical compositions containing the same | |
IL157740A0 (en) | Heterocyclic derivatives and pharmaceutical compositions containing the same | |
IL147214A0 (en) | 1-methylcarbapenem derivatives and pharmaceutical compositions containing the same | |
HUP0303184A3 (en) | Substituted c-cyclohexylmethylamine derivatives and pharmaceutical compositions containing them |